Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C43H48F3N5O5 |
Molecular Weight | 771.8669 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC1=CC=CC(=C1)C(F)(F)F)C(=O)[C@@H](CC(=O)N2CCC(CC2)N3CCCCC3)N4[C@H](\C=C\C5=CC=CC=C5)[C@H](N6[C@H](COC6=O)C7=CC=CC=C7)C4=O
InChI
InChIKey=GOQPVIZMGXUXOL-GRLAPFOSSA-N
InChI=1S/C43H48F3N5O5/c1-47(28-31-14-11-17-33(26-31)43(44,45)46)40(53)36(27-38(52)49-24-20-34(21-25-49)48-22-9-4-10-23-48)50-35(19-18-30-12-5-2-6-13-30)39(41(50)54)51-37(29-56-42(51)55)32-15-7-3-8-16-32/h2-3,5-8,11-19,26,34-37,39H,4,9-10,20-25,27-29H2,1H3/b19-18+/t35-,36-,37-,39+/m1/s1
Molecular Formula | C43H48F3N5O5 |
Molecular Weight | 771.8669 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:29:49 GMT 2023
by
admin
on
Sat Dec 16 11:29:49 GMT 2023
|
Record UNII |
G9Z22EU5FK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11686429
Created by
admin on Sat Dec 16 11:29:49 GMT 2023 , Edited by admin on Sat Dec 16 11:29:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545146
Created by
admin on Sat Dec 16 11:29:49 GMT 2023 , Edited by admin on Sat Dec 16 11:29:49 GMT 2023
|
PRIMARY | |||
|
512784-94-0
Created by
admin on Sat Dec 16 11:29:49 GMT 2023 , Edited by admin on Sat Dec 16 11:29:49 GMT 2023
|
PRIMARY | |||
|
G9Z22EU5FK
Created by
admin on Sat Dec 16 11:29:49 GMT 2023 , Edited by admin on Sat Dec 16 11:29:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Neuropsychotherapeutic; Mechanism of Action: Vasopressin 1 receptor antagonist; Highest Development Phases: Preclinical for Aggression, Discontinued for Dysmenorrhoea; Most Recent Events: 11 Jan 2010 SRX 251 is still in active development, 10 Dec 2009 Preclinical pharmacodynamics data presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009), 04 Oct 2006 Data presented at the 232nd National Meeting of the American Chemical Society (232nd-ACS-2006) have been added to the pharmacokinetics and Women's Health pharmacodynamics sections
|